EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population Genomic Screening and Improved Lipid Management in Patients With Familial Hypercholesterolemia

Matthew E Levy iD, Kelly M Schiabor Barrett iD, Megan N Betts iD, David Kann, Alexandre Bolze iD, Basil Khuder iD, Natalie Telis, Lisa M McEwen iD, Amy C Sturm iD, Chad Haldeman-Englert iD, Jeremy Cauwels iD, Douglas Stoller iD und 9 weitere

Circulation: Genomic and Precision Medicine · 2025

DOI: 10.1161/circgen.125.005206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2025. Verfasst von Matthew E Levy und 20 weiteren Autor:innen. Beteiligte Einrichtung: Helix, San Mateo, CA (M.E.L., K.M.S.B., A.B., B.K., N.T., L.M.M., N.L.W., W.L., E.T.C., C.H.). Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Genetic Testing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Helix Research Network program is a large population genomics initiative that screens an all-comers population of patients for Centers for Disease Control and Prevention Tier 1 genetic conditions, including familial hypercholesterolemia (FH). We evaluated changes in clinical management and low-density lipoprotein cholesterol (LDL-C) levels among patients we identified to have FH. METHODS: Participants across 9 US health systems provided samples that underwent clinical-grade exome sequencing. Individuals with a positive screening result for a Tier 1 condition were offered no-cost genetic counseling through their health system. Using medication and laboratory testing records, we evaluated changes in patients’ lipid-lowering therapies and LDL-C levels. RESULTS: Among 228 602 adults enrolled between 2017 to 2025, 1155 (≈1/198) had a pathogenic FH variant in LDLR (74%), APOB (25%), or PCSK9 (1%). Of the 622 with retrospective and prospective electronic health record data available (mean of 11.8 and 2.1 years, respectively), 84% lacked a prior clinical FH diagnosis. Overall, 33% received new/modified lipid-lowering therapy within the first year, but this proportion was higher in those with a newly documented FH diagnosis code (57% versus 17% for those without documentation; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IIGenetic TestingHumansFemaleMaleMiddle AgedAdultCholesterol, LDLProprotein Convertase 9Receptors, LDLGenomicsAgedExome SequencingApolipoprotein B-100

Stichwörter der Autor:innen

cholesterol, LDLexome sequencinggenetic testinggenomicshyperlipoproteinemia type IIhypolipidemic agentprecision medicine

Substanzen

Cholesterol, LDLProprotein Convertase 9PCSK9 protein, humanReceptors, LDLLDLR protein, humanApolipoprotein B-100APOB protein, human

Autor:innen und Institutionen

  • Helix, San Mateo, CA (M.E.L., K.M.S.B., A.B., B.K., N.T., L.M.M., N.L.W., W.L., E.T.C., C.H.).
  • Center for Inherited Cardiovascular Diseases, WellSpan Health, Ephrata, PA (M.N.B., D.K., C.A.A.C.).
  • The Ohio State University Wexner Medical Center, Columbus (A.C.S.).
  • Cone Health Precision Health, Greensboro, NC (C.H.-E.).
  • Sanford Health, Sioux Falls, SD (J.C.).
  • University of Nebraska Medical Center, Omaha (D.S.).

ORCID-Profile: Matthew E Levy, Kelly M Schiabor Barrett, Megan N Betts, Alexandre Bolze, Basil Khuder, Lisa M McEwen, Amy C Sturm, Chad Haldeman-Englert, Jeremy Cauwels, Douglas Stoller, C Anwar A Chahal, Joseph J Grzymski, Nicole L Washington, William Lee, Elizabeth T Cirulli, Catherine Hajek

Zitieren

APA

Levy, M. E., Schiabor Barrett, K. M., Betts, M. N., Kann, D., Bolze, A., Khuder, B., Telis, N., McEwen, L. M., Sturm, A. C., Haldeman-Englert, C., Cauwels, J., Stoller, D., Chahal, C. A. A., Chapman, C. N., Waring, A. A., Olson, D. A., Grzymski, J. J., Washington, N. L., Lee, W., …, & Hajek, C. (2025). Population Genomic Screening and Improved Lipid Management in Patients With Familial Hypercholesterolemia. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.125.005206

Vancouver

Levy ME, Schiabor Barrett KM, Betts MN, Kann D, Bolze A, Khuder B, et al. Population Genomic Screening and Improved Lipid Management in Patients With Familial Hypercholesterolemia. Circulation: Genomic and Precision Medicine. 2025. doi:10.1161/circgen.125.005206

BibTeX
@article{Levy2025,
  author = {Levy, Matthew E and Schiabor Barrett, Kelly M and Betts, Megan N and Kann, David and Bolze, Alexandre and Khuder, Basil and Telis, Natalie and McEwen, Lisa M and Sturm, Amy C and Haldeman-Englert, Chad and Cauwels, Jeremy and Stoller, Douglas and Chahal, C Anwar A and Chapman, Christopher N and Waring, Ashley A and Olson, Douglas A and Grzymski, Joseph J and Washington, Nicole L and Lee, William and Cirulli, Elizabeth T and Hajek, Catherine},
  title = {Population Genomic Screening and Improved Lipid Management in Patients With Familial Hypercholesterolemia},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2025},
  doi = {10.1161/circgen.125.005206}
}
Kostenlos starten →